NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

NCT06651151 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage IIIB-IV

Interventions

DRUG: LTX-315 + pembrolizumab

Sponsor

Oslo University Hospital

Collaborators

[object Object]